Search

Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder

Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...

GentleCath™ intermittent catheters

We know that Urinary Tract Infections (UTIs) are the biggest issue for catheter users. In the United Kingdom, 14 million people suffer from continence problems1. Although hydrophilic coated catheters (2nd generation) brought benefits compared to uncoated catheters (1st generation), users...

Prolapse surgery with mesh: where do we stand in 2017? An ICS update

Background Surgery for pelvic organ prolapse (POP) is common among women. The lifetime risk of undergoing at least one surgical procedure for POP is up to 20% [1]. This kind of surgery will be increasingly important due to an ageing...

Erectile dysfunction part II: treatment

Introduction The identification of specific risk factors associated with erectile dysfunction (ED) allows patients with mild or moderate ED to undergo a series of lifestyle changes, which may provide enough improvement in the erectile function to avoid pharmacotherapies. Cessation of...

Bladder cancer diagnosis and follow up: A new proven urinary biomarker to support the post COVID-19 recovery phase

Since lockdown began most urologists have been following the advice of BAUS Oncology, to minimise the risk of exposure of patients and staff to potential COVID-19 infection: the result is an increasing backlog of patients requiring tests to determine if...

Recent developments in bladder cancer – NMIBC

Every year, roughly 10,300 individuals are diagnosed with bladder cancer in the UK, making it the 11th most common cancer in the UK, and the eighth most common cancer in men [1]. Of those diagnosed with the disease, 75-85% will...